Zentiva is delighted to announce its endorsement for the European Commission’s Critical Medicines Act, a crucial initiative toward ensuring the availability of essential medicines and enhancing pharmaceutical manufacturing across Europe.

For decades, critical medicines have played a vital role in saving lives and improving the health of millions. However, their availability and supply stability face increasing challenges. The European Union’s list of critically important medicines includes more than 270 active substances, with 90% being generics—a cornerstone of accessible healthcare.

The Critical Medicines Act introduces strategic investments, improved stockpiling measures, and optimized procurement regulations, laying the groundwork for a more resilient and sustainable supply chain.

While this represents a significant milestone, it is imperative that we advance further. Concentrating only on today’s critical medicines is insufficient, as millions of individuals rely on a broader range of medicines daily.

To establish a truly resilient system, it is crucial to: 

• Invest in European-based medicine production to reduce supply risks 
• Reform procurement rules to prioritize reliability and sustainability, not just the lowest price 
• Ensure financial and regulatory support for off-patent manufacturers of medicines 
• Strengthen supply chain resilience beyond the currently listed critical medicines

Zentiva is dedicated to collaborating with all stakeholders to realize this vision. It is imperative that we ensure continued access to essential medicines for the people of Europe. Decisive action is required today to ensure a sustainable future for all generations.